1. Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.
- Author
-
Durinikova, Anna, Folta, Adam, Pardy, Filip, Svaton, Jan, Drncova, Marie, Weinbergerova, Barbora, Cetkovsky, Petr, Racil, Zdenek, Jindra, Pavel, Szotkowski, Tomas, Zak, Pavel, Mayer, Jiri, and Jeziskova, Ivana
- Subjects
ACUTE myeloid leukemia ,GENETIC mutation - Abstract
Similarly, nanopore analysis performed in 6/16 patients with simultaneously detected mutations in codons Gly12 and Gln61 or Gly13 and Gln61 did not reveal any patients with the presence of these mutations together on the same I NRAS i gene's allele. Oncogenic mutations in the I NRAS i gene are carried by 10-22% acute myeloid leukemia (AML) patients and represent one of the most commonly detected molecular aberrations in AML [[1], [3], [5]]. There was no significant difference in CR rate (89.5% vs. 75.0%, I p i = 0.2109), OS (33 months vs. undefined, I p i = 0.4300) or EFS (10 vs. 9 months, I p i = 0.6191) between patients with single I NRAS i mutation vs. patients with multiple I NRAS i mutations, respectively. NGS results from 5/16 patients with simultaneously detected multiple point mutations in codons Gly12 and Gly13 did not reveal any patients carrying these mutations on the same I NRAS i gene's allele. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF